Key Points Jaguar Health reported that an infant with a rare genetic form of intestinal failure needed approximately 15% less daily parenteral support after several…
October 21, 2026
Opus Genetics Gets FDA Clearance to Begin Gene Therapy Trial for Inherited Childhood Blindness
Key Points The FDA cleared Opus Genetics’ application to begin clinical testing of OPGx-RDH12 for a rare inherited retinal disease. Opus plans to initiate a…
October 21, 2026
Invivyd Reports Encouraging Lab Results for Measles Antibody, Targets Clinical Development in 2027
Key Points Invivyd presented preclinical findings for VMS063, an experimental antibody being developed to treat and prevent measles. Laboratory testing showed potent antiviral activity against…
October 20, 2026
Palisade Bio Reports Early Crohn’s Disease Improvements as PALI-2108 Advances in Phase 2
Key Points Five Crohn’s disease patients showed a 47.5% reduction in average endoscopic disease activity after 14 days of PALI-2108 treatment. Average fecal calprotectin, a…
October 20, 2026
PRISM Mid-Day Movers: Biotech and New Energy are Today’s Leaders
Myriad Genetics (NASDAQ: MYGN) shares surged today, rising $1.55, or 36.70%, to $5.76 by midday, according to Yahoo Finance’s latest news quote. The rally followed…
Key Points Personalis commercially launched Real-Time Variant Tracker as an optional addition to its NeXT Personal molecular residual disease test report. The supplemental results track…
Key Points Myriad Genetics agreed to sell its Prenatal Health testing business to Labcorp for $210 million in cash, plus the value of inventory at…
October 20, 2026
Vivos Closes SOD Sciences Deal, Targeting Potential Access to More Than 325,000 Patients
Key Points Vivos acquired an 11% fully diluted stake in SOD Sciences and 50% co-ownership of its experimental pseudohypoxia test. The company paid with convertible…
Key Points Merck KGaA, Darmstadt, Germany, agreed to acquire Silence Therapeutics for $20 per American Depositary Share in cash. The offer represents a 130% premium…
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) shares rose about 21% to roughly $1.37 by mid-day Monday, up from Friday’s $1.13 close. The rally came as Actinium…
Key Points NRx Pharmaceuticals completed three commercial-scale validation lots of its preservative-free ketamine. Two-year room-temperature testing showed no deterioration in purity, potency or sterility, according…
Key Points Daré Bioscience is the premier sponsor of a clinician education program focused on managing menopause after breast cancer. The October 20 event in…